ストックスクリーナーアプリを入手
219.63
0.74%
-0.125
Resmed Inc (RMD) 最新ニュース
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
ResMed (NYSE:RMD) Reaches New 52-Week LowWhat's Next? - MarketBeat
ResMed Inc stock hits 52-week low at 218.27 USD - Investing.com
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Resmed's Q3 Earnings on Deck: What's in Store for the Stock? - TradingView
ResMed Inc. $RMD Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Reduces Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed (RMD) Projected to Post Earnings on Thursday - MarketBeat
Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsight - GlobeNewswire Inc.
OVERSEA CHINESE BANKING Corp Ltd Sells 7,795 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Mirae Asset Global Investments Co. Ltd. Boosts Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc stock (US75102W1036): Is its sleep apnea dominance strong enough for long-term investor g - AD HOC NEWS
ResMed Inc. stock (US7611521078): Is its sleep apnea dominance strong enough for long-term investor - AD HOC NEWS
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance Singapore
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again - Yahoo Finance
ResMed Inc. stock (US7611521078): Is the U.S. sleep apnea market strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. (RMD) Investor Outlook: Unveiling a 28% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
RMD Stock Price, Quote & Chart | RESMED INC (NYSE:RMD) - ChartMill
JPMorgan Issues Overweight Rating for ResMed Amid Sleep Apnea Shift - HarianBasis.co
JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT - Insider Monkey
Mizuho Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - MSN
Lbp Am Sa Buys 18,142 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Should you continue to hold Resmed stock in your portfolio? - MSN
Should You Continue to Hold Resmed Stock in Your Portfolio? - TradingView
KBC Group NV Has $57.23 Million Position in ResMed Inc. $RMD - MarketBeat
Hendershot Investments Inc. Increases Holdings in ResMed Inc. $RMD - MarketBeat
INVESCO V.I. Health Care Fund's ResMed Inc(RMD) Holding History - GuruFocus
ResMed, Inc. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares? - The Motley Fool Australia
ResMed Inc. stock (US7611521078): Why does its sleep apnea dominance matter more now? - AD HOC NEWS
ResMed (NYSE:RMD) Now Covered by JPMorgan Chase & Co. - MarketBeat
Baird Adjusts Price Target on ResMed to $254 From $272, Maintains Neutral Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
ResMed Inc. stock (US7611521078): Is sleep apnea market growth strong enough to unlock new upside? - AD HOC NEWS
ResMed Inc. $RMD Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
RMD Analyst Rating Maintained at Outperform by Evercore ISI - Meyka
ResMed Inc (NYSE:RMD): A Durable Dividend Growth Stock for Passive Income - ChartMill
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Ord Minnett - The Globe and Mail
ResMed Inc. (RMD) Stock Analysis: Exploring a 29.56% Upside Potential with Robust Revenue Growth - DirectorsTalk Interviews
Wells Fargo Analyst Raises ResMed (RMD) Price Target to $270 | R - GuruFocus
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Trade Ideas — LSX:935168 - TradingView
ResMed Faces Shifting Market Signals in Healthcare Space - Kalkine Media
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Citigroup Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - MarketBeat
Resmed CEO Farrell sells $1.12 million in stock - Investing.com
Resmed CEO Farrell sells $1.12 million in stock By Investing.com - Investing.com Australia
ResMed (RMD) CEO Farrell sells 4,991 shares after option exercise - Stock Titan
ResMed Insider Selling Raises Questions On Management Conviction And Valuation - Sahm
ResMed Inc. stock rises Wednesday, still underperforms market - MarketWatch
Citigroup Adjusts Price Target on ResMed to $340 From $345, Maintains Buy Rating - marketscreener.com
ResMed Inc. $RMD Shares Sold by Pacific Point Advisors LLC - MarketBeat
ResMed CEO Michael Farrell Plans Additional Insider Sale Under Rule 144 - TipRanks
Affiliate plans sale of 4,991 RMD shares via Fidelity (NYSE: RMD) - Stock Titan
Is Now The Time To Put ResMed (NYSE:RMD) On Your Watchlist? - Moomoo
Robinhood Asset Management Boosts ResMed Stake - National Today
Sleep Apnea Devices Market to Reach Strong Growth Through 2033 - openPR.com
ResMed Adjusts CDI and Share Balances Amid Transfers, Equity Issuance and Buybacks - TipRanks
ResMed Officer Sandercock Discloses Ongoing Insider Share Sales Under Rule 144 - TipRanks
0.68%
0.61%
大文字化:
|
ボリューム (24 時間):